Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.  Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for rare and more prevalent neurological disorders.We share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders.Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue						2.45M -
cost of revenue		679K -	746K 9.87%	1.59M 113.67%	1.17M 26.54%	432K 63.11%
gross profit		-679K -	-746K 9.87%	-1.59M 113.67%	-1.17M 26.54%	2.02M 272.08%
selling and marketing expenses
general and administrative expenses	3.90M -	6.23M 59.84%	16.99M 172.66%	47.08M 177.04%	59.95M 27.34%	42.05M 29.85%
selling general and administrative expenses	3.90M -	6.23M 59.84%	16.99M 172.66%	47.08M 177.04%	59.95M 27.34%	42.05M 29.85%
research and development expenses	18.82M -	29.56M 57.05%	44.98M 52.17%	120.26M 167.38%	155.04M 28.92%	86.77M 44.04%
other expenses	-3.65M -		140K -	271K 93.57%	957K 253.14%	3.10M 223.51%
cost and expenses	22.72M -	35.79M 57.53%	61.97M 73.15%	167.33M 170.03%	214.99M 28.48%	128.82M 40.08%
operating expenses	22.72M -	35.79M 57.53%	61.97M 73.15%	167.33M 170.03%	214.99M 28.48%	128.82M 40.08%
interest expense	127K -				-419K -
ebitda	-26.27M -	-35.56M 35.34%	-61.97M 74.27%	-167.33M 170.03%	-214.99M 28.48%	-125.94M 41.42%
operating income	-22.72M -	-35.79M 57.53%	-61.97M 73.15%	-167.33M 170.03%	-214.99M 28.48%	-126.37M 41.22%
depreciation and amortization	1K -	230K 22,900%	50K 78.26%	182K 264%	419K 130.22%	432K 3.10%
total other income expenses net	-3.65M -	193K 105.29%	140K 27.46%	271K 93.57%	957K 253.14%	3.10M 223.51%
income before tax	-26.40M -	-35.60M 34.82%	-61.83M 73.69%	-167.06M 170.20%	-214.03M 28.11%	-123.28M 42.40%
income tax expense	133K -	-84K 163.16%	-8K 90.48%	-182K 2,175%	-957K 425.82%
net income	-26.54M -	-35.51M 33.83%	-61.82M 74.08%	-166.88M 169.94%	-213.07M 27.68%	-123.28M 42.14%
weighted average shs out	13.27M -	2.55M 80.78%	2.55M 0.05%	2.83M 10.94%	3.07M 8.58%	6.59M 114.58%
weighted average shs out dil	13.27M -	2.55M 80.78%	2.55M 0.05%	2.83M 10.94%	3.07M 8.58%	6.59M 114.58%
eps	-2 -	-13.93 596.50%	-24.23 73.94%	-58.96 143.33%	-69.33 17.59%	-18.69 73.04%
epsdiluted	-2 -	-13.93 596.50%	-24.23 73.94%	-58.96 143.33%	-69.33 17.59%	-18.69 73.04%

PRAX

NASDAQ:PRAX

Praxis Precision Medicines

Last Close

57.54

26/07 20:00

Market Cap

819.81M

Beta: 3.01

Volume Today

145.59K

Avg: 1.66M

PE Ratio

−41.39

PFCF: −3.16

Preview